As per my two colleagues, I'd like to thank the committee for the opportunity to appear before it to try to provide clarity on the role of Health Canada in the oversight of products, and, as their safety profile evolves, on the steps we take to ensure that the labelling adequately represents the evolving understanding of the benefits and risks. Hopefully, the information we provided today has helped the committee understand. This is a very complex study you're carrying out. We look forward to the recommendations.
On November 3rd, 2016. See this statement in context.